Revenue
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | £20.0M | £19.6M | £10.6M | £21.0M | N/A |
| Research & development | £4.1M | £2.8M | £2.9M | £5.0M | N/A |
| Operating expenses | £25.0M | £28.7M | £19.3M | £21.4M | N/A |
| Operating income | −£12.4M | £3.4M | −£15.8M | −£15.7M | N/A |
| Operating margin | −61.80% | 17.14% | −149.02% | −74.50% | N/A |
| EBITDA | −£8.2M | −£31.4M | −£12.4M | −£11.7M | N/A |
| EBITDA margin | −40.85% | −159.86% | −116.61% | −55.50% | N/A |
| Net income | −£22.9M | −£41.8M | −£28.3M | −£25.7M | N/A |
| Net profit margin | −114.25% | −212.73% | −266.38% | −122.29% | N/A |
| Basic EPSper basic share | N/A | -£0.59 | -£0.40 | -£0.36 | -£0.14 |
| Diluted EPSper diluted share | N/A | -£0.59 | -£0.40 | -£0.36 | -£0.14 |
Reported ownership
Novacyt ($NCYT) reported first-half revenue growth of 18% to £11.6 million, with approximately 9% underlying growth excluding acquired Southern Cross Diagnostics. Instrumentation sales increased about 30%, while clinical products grew more ...